Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CR 4056

Next Previous
Drug Profile

CR 4056

Alternative Names: CR4056

Latest Information Update: 01 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rottapharm Madaus
  • Developer Rottapharm Biotech; Rottapharm Madaus
  • Class Analgesics; Imidazolines; Small molecules
  • Mechanism of Action Imidazoline I2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain
  • No development reported Acute pain; Cancer pain; Neuropathic pain

Most Recent Events

  • 30 Nov 2022 CR 4056 is still in phase II clinical development for Pain in Poland and United Kingdom (Rottapharm Biotech pipeline, November 2022)
  • 24 Sep 2020 Clinical development for Pain is underway in Poland and United Kingdom (Rottapharm Biotech website, September 2020)
  • 15 Jul 2020 Rottapharm Biotech completes four phase I clinical trials (In volunteers), prior to July 2020 (Rottapharm Biotech pipeline, July 2020).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top